Overview

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

Status:
Recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, double-dummy, placebo- and active-controlled 4 period, 4 way crossover study to assess the intranasal abuse potential of manipulated ADAIR formulation in nondependent, recreational stimulant users. The study will consist of an outpatient Screening Visit, an in clinic Qualification Phase, an in-clinic Treatment Phase, and an outpatient Follow-Up visit.

Phase:

Phase 1

Details

Lead Sponsor:

Vallon Pharmaceuticals, Inc.

Treatments:

Amphetamine
Dextroamphetamine